利妥昔单抗治疗IgG4相关垂体炎:18F-FDG PET与MRI疗效评估
一例IgG4相关垂体炎患者基线18F-FDG PET和MRI显示15 mm富血供高代谢病灶伴鞍区及鞍上延伸。一线糖皮质激素治疗10个月后PET和MRI均显示无响应。后续2次1 g利妥昔单抗联合持续激素治疗3个月后,MRI示垂体病灶显著缩小、残留钆增强极少,而18F-FDG PET显示完全代谢响应。
要点
- IgG4相关垂体炎基线可表现为高代谢富血供病灶,18F-FDG PET与MRI可联合评估。
- 一线激素治疗10个月无响应时,PET和MRI均未见改善。
- 利妥昔单抗联合激素治疗后PET达完全代谢响应,MRI示病灶显著缩小。
核心结论
- 联合18F-FDG PET与MRI评估可能对垂体IgG4相关疾病的治疗响应评价有潜在价值。
研究设计与样本
- 单例病例报告,对一例IgG4相关垂体炎患者进行基线及治疗后的18F-FDG PET和MRI评估。
主要发现
- 基线18F-FDG PET和MRI显示15-mm富血供高代谢病灶,伴鞍区及鞍上延伸。
- 一线糖皮质激素治疗10个月后,18F-FDG PET和MRI均显示无响应。
- 2次1 g利妥昔单抗联合持续激素治疗3个月后,MRI示垂体病灶显著缩小、残留钆增强极少。
- 同时间点18F-FDG PET显示完全代谢响应。
临床怎么用
- 对IgG4相关垂体炎患者,治疗期间可考虑联合18F-FDG PET与MRI评估治疗响应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Baseline F-FDG PET and MRI were performed in a patient with IgG4-related hypophysitis, showing a 15-mm hypervascular hypermetabolic lesion with sellar and suprasellar extension. Lack of response after 10 months of first-line corticosteroid therapy was demonstrated on both F-FDG PET and MRI. Three months later, after 2 injections of 1 g of rituximab associated with continued corticosteroid therapy, MRI showed substantial shrinkage of the pituitary lesion with minimal residual Gd enhancement, whereas F-FDG PET evidenced complete metabolic response. As such, joint F-FDG PET and MRI assessment during therapy may have a potential interest for treatment response evaluation in pituitary IgG4-related disease.
引用
- Vauchot F, Bourdon A, Hay B, et al. Therapeutic Response to Rituximab in IgG4-Related Hypophysitis Evidenced on 18F-FDG PET and MRI. Clin Nucl Med. 2019. PMID: 30829857. doi:10.1097/RLU.0000000000002514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。